Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
28 Aug 2019
Historique:
received: 12 03 2019
accepted: 05 08 2019
entrez: 29 8 2019
pubmed: 29 8 2019
medline: 4 3 2020
Statut: epublish

Résumé

There is a relationship between Chronic Obstructive Pulmonary Disease (COPD) and the development of lung cancer (LC). The aim of this study is to analyse several blood markers and compare their concentrations in patients with only COPD and LC + COPD. Case-control study with cases presenting combined LC and COPD and two control groups (patients presenting only COPD and patients presenting only LC). We also included LC patients with descriptive purposes. In both groups, peripheral blood analyses of TNF-α, IL-6, IL-8, total leukocyte, lymphocyte and neutrophil counts, neutrophil-to-lymphocyte ratio, total platelet count, mean platelet volume, platelet-to-lymphocyte ratio, alpha 1-antitripsin (A1AT), IgE, C-reactive protein, fibrinogen, cholesterol and bilirubin were performed. We developed univariate and multivariate analyses of these markers, as well as a risk score variable, and we evaluated its performance through ROC curves. We included 280 patients, 109 cases (LC + COPD), 83 controls (COPD) and 88 LC without COPD. No differences were observed in the distribution by sex, age, BMI, smoking, occupational exposure, lung function, GOLD stage or comorbidity. Patients with LC + COPD had significantly higher levels of neutrophils [OR 1.00 (95%CI 1.00-1.00), p = 0.03] and A1AT [OR 1.02 (95%CI 1.01-1.03), p = 0.003] and lower cholesterol levels [OR 0.98 (95%CI 0.97-0.99), p = 0.009] than COPD controls. We developed a risk score variable combining neutrophils, A1AT and cholesterol, achieving a sensitivity of 80%, a negative predictive value of 90.7% and an area under the curve of 0.78 (95%CI 0.71-0.86). COPD patients who also have LC have higher levels of neutrophils and A1AT and lower of cholesterol. These parameters could be potentially predicting biomarkers of LC in COPD patients.

Sections du résumé

BACKGROUND BACKGROUND
There is a relationship between Chronic Obstructive Pulmonary Disease (COPD) and the development of lung cancer (LC). The aim of this study is to analyse several blood markers and compare their concentrations in patients with only COPD and LC + COPD.
METHODS METHODS
Case-control study with cases presenting combined LC and COPD and two control groups (patients presenting only COPD and patients presenting only LC). We also included LC patients with descriptive purposes. In both groups, peripheral blood analyses of TNF-α, IL-6, IL-8, total leukocyte, lymphocyte and neutrophil counts, neutrophil-to-lymphocyte ratio, total platelet count, mean platelet volume, platelet-to-lymphocyte ratio, alpha 1-antitripsin (A1AT), IgE, C-reactive protein, fibrinogen, cholesterol and bilirubin were performed. We developed univariate and multivariate analyses of these markers, as well as a risk score variable, and we evaluated its performance through ROC curves.
RESULTS RESULTS
We included 280 patients, 109 cases (LC + COPD), 83 controls (COPD) and 88 LC without COPD. No differences were observed in the distribution by sex, age, BMI, smoking, occupational exposure, lung function, GOLD stage or comorbidity. Patients with LC + COPD had significantly higher levels of neutrophils [OR 1.00 (95%CI 1.00-1.00), p = 0.03] and A1AT [OR 1.02 (95%CI 1.01-1.03), p = 0.003] and lower cholesterol levels [OR 0.98 (95%CI 0.97-0.99), p = 0.009] than COPD controls. We developed a risk score variable combining neutrophils, A1AT and cholesterol, achieving a sensitivity of 80%, a negative predictive value of 90.7% and an area under the curve of 0.78 (95%CI 0.71-0.86).
CONCLUSIONS CONCLUSIONS
COPD patients who also have LC have higher levels of neutrophils and A1AT and lower of cholesterol. These parameters could be potentially predicting biomarkers of LC in COPD patients.

Identifiants

pubmed: 31455338
doi: 10.1186/s12931-019-1155-2
pii: 10.1186/s12931-019-1155-2
pmc: PMC6712782
doi:

Substances chimiques

Biomarkers 0
Inflammation Mediators 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

198

Subventions

Organisme : Sociedad Española de Neumología y Cirugía Torácica
ID : p110/2016

Références

Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Oncol Res. 2007;16(8):375-81
pubmed: 17913045
Am J Med. 2008 Jan;121(1):3-9
pubmed: 18187064
Respir Med. 2009 May;103(5):692-9
pubmed: 19131231
Eur Respir J. 2009 Aug;34(2):380-6
pubmed: 19196816
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
JAMA. 2011 Feb 16;305(7):691-7
pubmed: 21325185
Lung Cancer. 2012 Apr;76(1):61-6
pubmed: 21945657
Arch Bronconeumol. 2012 Jul;48(7):247-57
pubmed: 22561012
PLoS One. 2012;7(5):e37483
pubmed: 22624038
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Free Radic Biol Med. 2013 Dec;65:859-871
pubmed: 23954470
Int Immunopharmacol. 2013 Dec;17(4):1211-7
pubmed: 23994347
COPD. 2014 Aug;11(4):388-400
pubmed: 24111878
Thorax. 2014 Jul;69(7):666-72
pubmed: 24310110
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Clin Chest Med. 2014 Mar;35(1):131-41
pubmed: 24507841
ScientificWorldJournal. 2014 Jan 21;2014:140736
pubmed: 24587707
J Korean Med Sci. 2014 Apr;29(4):507-11
pubmed: 24753697
Arch Bronconeumol. 2014 Oct;50(10):417-21
pubmed: 24814028
Int J Biochem Cell Biol. 2014 Aug;53:77-88
pubmed: 24853773
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Respir Res. 2014 Oct 29;15:130
pubmed: 25359094
Wien Klin Wochenschr. 2015 Oct;127(19-20):756-63
pubmed: 25586444
Lung Cancer. 2015 Apr;88(1):42-7
pubmed: 25698134
Ann Oncol. 2015 Aug;26(8):1784-90
pubmed: 25969367
Lung Cancer. 2015 Nov;90(2):121-7
pubmed: 26363803
Respir Care. 2016 Jan;61(1):44-9
pubmed: 26604328
Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2469-78
pubmed: 26648709
EBioMedicine. 2015 Nov;2(11):1677-85
pubmed: 26870794
Arch Bronconeumol. 2016 May;52 Suppl 1:2-62
pubmed: 27389767
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Sci Rep. 2016 Nov 04;6:36065
pubmed: 27811960
Am J Epidemiol. 2017 Jan 15;185(2):86-95
pubmed: 27998891
Contemp Oncol (Pozn). 2016;20(5):407-413
pubmed: 28373824
Int J Oncol. 2017 Jun;50(6):1955-1964
pubmed: 28440399
Arch Bronconeumol. 2017 Jun;53(6):324-335
pubmed: 28477954
Oncotarget. 2017 Dec 12;9(1):892-900
pubmed: 29416664
J Clin Med. 2018 Jun 25;7(7):null
pubmed: 29941786
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716

Auteurs

Cecilia Mouronte-Roibás (C)

Pulmonary Department, Hospital Álvaro Cunqueiro, Vigo Health Area; NeumoVigoI+i Research Group, Vigo Biomedical Research Institute (IBIV), Vigo, Spain.

Virginia Leiro-Fernández (V)

Pulmonary Department, Hospital Álvaro Cunqueiro, Vigo Health Area; NeumoVigoI+i Research Group, Vigo Biomedical Research Institute (IBIV), Vigo, Spain. virginia.leiro.fernandez@sergas.es.

Alberto Ruano-Raviña (A)

University of Santiago de Compostela, Preventive Medicine and Public Health. School of Medicine, San Francisco st s/n Santiago de Compostela, A Coruña, Spain.
CIBER de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.

Cristina Ramos-Hernández (C)

Pulmonary Department, Hospital Álvaro Cunqueiro, Vigo Health Area; NeumoVigoI+i Research Group, Vigo Biomedical Research Institute (IBIV), Vigo, Spain.

Pedro Casado-Rey (P)

Clinical Analysis Department, Hospital Álvaro Cunqueiro, Vigo Health Area, Vigo, Spain.

Maribel Botana-Rial (M)

Pulmonary Department, Hospital Álvaro Cunqueiro, Vigo Health Area; NeumoVigoI+i Research Group, Vigo Biomedical Research Institute (IBIV), Vigo, Spain.

Esmeralda García-Rodríguez (E)

Pulmonary Department, Hospital Álvaro Cunqueiro, Vigo Health Area; NeumoVigoI+i Research Group, Vigo Biomedical Research Institute (IBIV), Vigo, Spain.

Alberto Fernández-Villar (A)

Pulmonary Department, Hospital Álvaro Cunqueiro, Vigo Health Area; NeumoVigoI+i Research Group, Vigo Biomedical Research Institute (IBIV), Vigo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH